EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade

Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino iD, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss iD und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Cesare Di Nitto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Philochem AG, Otelfingen, Switzerland. Hauptthemen laut MEDLINE: Fibronectins, CD8-Positive T-Lymphocytes, Interleukin-7. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-PD-1 antibodies have revolutionized cancer immunotherapy due to their ability to induce long-lasting complete remissions in a proportion of patients. Current research efforts are attempting to identify biomarkers and suitable combination partners to predict or further improve the activity of immune checkpoint inhibitors. Antibody-cytokine fusions are a class of pharmaceuticals that showed the potential to boost the anticancer properties of other immunotherapies. Extradomain A-fibronectin (EDA-FN), which is expressed in most solid and hematological tumors but is virtually undetectable in healthy adult tissues, is an attractive target for the delivery of cytokine at the site of the disease.

Methods

In this work, we describe the generation and characterization of a novel interleukin-7-based fusion protein targeting EDA-FN termed F8(scDb)-IL7. The product consists of the F8 antibody specific to the alternatively spliced EDA of FN in the single-chain diabody (scDb) format fused to human IL-7.

Results

F8(scDb)-IL7 efficiently stimulates human peripheral blood mononuclear cells in vitro. Moreover, the product significantly increases the expression of T Cell Factor 1 (TCF-1) on CD8+T cells compared with an IL2-fusion protein. TCF-1 has emerged as a pivotal transcription factor that influences the durability and potency of immune responses against tumors. In preclinical cancer models, F8(scDb)-IL7 demonstrates potent single-agent activity and eradicates sarcoma lesions when combined with anti-PD-1.

Conclusions

Our results provide the rationale to explore the combination of F8(scDb)-IL7 with anti-PD-1 antibodies for the treatment of patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibronectinsCD8-Positive T-LymphocytesInterleukin-7HumansAnimalsMiceRecombinant Fusion ProteinsProgrammed Cell Death 1 ReceptorNeoplasmsHepatocyte Nuclear Factor 1-alphaImmune Checkpoint InhibitorsUp-RegulationFemaleCell Line, Tumor

Stichwörter der Autor:innen

Antibodies, BispecificCD8-Positive T-LymphocytesCombined Modality TherapyCytokinesImmune Checkpoint Inhibitors

Substanzen

FibronectinsInterleukin-7Recombinant Fusion ProteinsProgrammed Cell Death 1 ReceptorHepatocyte Nuclear Factor 1-alphaPDCD1 protein, humanImmune Checkpoint InhibitorsIL7 protein, humanHNF1A protein, human

Autor:innen und Institutionen

  • Philochem AG, Otelfingen, Switzerland.
  • Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
  • University of Zurich, Zurich, Switzerland.
  • Philogen SpA, Siena, Italy.
  • Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.

ORCID-Profile: Christian Pellegrino, Tobias Weiss, Roberto De Luca

Zitieren

APA

Di Nitto, C., Ravazza, D., Gilardoni, E., Look, T., Sun, M., Prodi, E., Moisoiu, V., Pellegrino, C., Manz, M. G., Puca, E., Weller, M., Weiss, T., Neri, D., & De Luca, R. (2024). An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008504

Vancouver

Di Nitto C, Ravazza D, Gilardoni E, Look T, Sun M, Prodi E, et al. An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008504

BibTeX
@article{DiNitto2024,
  author = {Di Nitto, Cesare and Ravazza, Domenico and Gilardoni, Ettore and Look, Thomas and Sun, Miaomiao and Prodi, Eleonora and Moisoiu, Vlad and Pellegrino, Christian and Manz, Markus G and Puca, Emanuele and Weller, Michael and Weiss, Tobias and Neri, Dario and De Luca, Roberto},
  title = {An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008504}
}
Kostenlos starten →